Cell MedX Corp. Rolls Out eBalance Pro Series Device for Diabetes Research
Manufacturing Is Underway and Anticipated to Significantly Boost Development Efforts
LAS VEGAS, NV– Cell MedX Corp. (OTCQB: CMXC) (“Cell MedX” or the “Company”), a development stage company focused on the commercialization of therapeutic devices for patients with diseases such as diabetes, is pleased to announce that as of late 2015 it had received and successfully tested its first eBalance Professional Series (Pro) device.
The eBalance Pro device is designed to study targeted effects on glucose control, increased insulin sensitivity and insulin resistance, abatement of diabetic neuropathy, accelerated wound healing as well as pain management for both non-diabetic and diabetic patients.
The initial eBalance Pro device is a first generation variable sensitivity unit controlled through a computer interface employing custom software to administer the therapeutic protocols. The initial Pro device was rigorously tested by the Cell MedX team and was found to perform better than anticipated. These positive results led the Company to commission the manufacture of an additional 25 units which are scheduled to arrive in February and are anticipated to significantly accelerate ongoing research efforts.
Cell MedX President and CEO Mr. Frank McEnulty states, “We are looking forward to getting these devices into the hands of researchers as quickly as possible. The new Pro model is faster and easier for physicians and clinical staff to employ, a factor which will help satisfy our ongoing need for quantifiable research data. We anticipate that practical use of the units will translate into potential for increased interest and future demand as we move forward towards commercialization. All in all an excellent start to the year and we wish all our shareholders and supporters great success in 2016.”
About Cell MedX Corp (OTCQB: CMXC)
Cell MedX Corp. is a development stage company focused on the commercialization of therapeutic products for patients with diseases such as diabetes by developing technologies to help manage the illness and related complications. For more information go to: www.cellmedx.comand visit us on Facebook.
On behalf of the Board of Directors of Cell MedX Corp.
Frank McEnulty
Chief Executive Officer and President.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects”, “aims”, “intends”, “estimates”, “projects”, “anticipates”, “believes”, “could”, “possibility” and other similar words. All statements addressing product performance, studies, revenues, demand, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on the Company’s forward-looking statements. In particular, the Company’s e-balance Technology is still in development. The Company does not currently have any commercially marketable products based on the e-balance technology, and there is no assurance that the Company will be successful in its development efforts. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.